Clinical Characteristics and Long-term Outcome of Patients With Generalized Patch and/or Plaque (T2) Mycosis Fungoides

Kim, Youn H.; Chow, Steve; Varghese, Anna; Hoppe, Richard T.

doi:10.1001/archderm.135.1.26

Cited by 148 publications

(105 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, in a subgroup of patients diagnosed with early MF, the disease follows a more aggressive and occasionally fatal clinical course. 4,5 Sézary syndrome (SS) is a less frequent but very aggressive form of CTCL characterized by erythroderma, generalized lymphadenopathy, and the presence of neoplastic T cells (Sézary cells) in the peripheral blood. 1 Interleukin (IL)-17A and IL-17F are 2 highly homologous proinflammatory cytokines that are produced by the Th17 subset of CD4 1 T cells.…”

Section: Introductionmentioning

confidence: 99%

Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma

Krejsgaard

Litvinov

Wei

et al. 2013

Blood

100

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma

Krejsgaard

Litvinov

Wei

et al. 2013

Blood

100

View full text Add to dashboard Cite

show abstract

“…Many patients remain at the same stage for prolonged periods; however, some progress from patch/plaque to skin tumors. 2,3 Large cell transformation associated with marked worsening of prognosis can also occur.…”

Section: Introductionmentioning

confidence: 99%

Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma

Kim¹,

Duvic

Obitz

et al. 2007

Blood

Self Cite

191

View full text Add to dashboard Cite

“…Although early (patch stage) mycosis fungoides often follows an indolent course, approximately one quarter of patients with generalized disease progress to a more advanced clinical stage, and Ն20% of these patients eventually die of the disease (7,8). Mycosis fungoides may also undergo transformation to cutaneous large T-cell lymphoma or present in a leukemic form termed Sezary syndrome, both of which have a grave prognosis (5,7).…”

mentioning

confidence: 99%

“…Mycosis fungoides may also undergo transformation to cutaneous large T-cell lymphoma or present in a leukemic form termed Sezary syndrome, both of which have a grave prognosis (5,7). Because a significant proportion of patients with mycosis fungoides undergo clinical progression associated with a high mortality, it may be important to initiate treatment early in the course of the disease.…”

mentioning

confidence: 99%

Galectin-1–Mediated Apoptosis in Mycosis Fungoides: The Roles of CD7 and Cell Surface Glycosylation

et al. 2003

View full text Add to dashboard Cite

Sezary cells, the malignant T cells in mycosis fungoides/Sezary syndrome, resist a variety of apoptosis-inducing agents, a feature that contributes to the poor response to therapy in mycosis fungoides. Galectin-1 is a mammalian lectin that triggers T cell apoptosis. For T cells to be susceptible to galectin-1-induced apoptosis, the T cells must express specific glycoprotein receptors, such as CD7, that bear the specific oligosaccharides recognized by galectin-1. Because Sezary cells are characteristically CD7 ؊ , lack of CD7 expression has been proposed to render Sezary cells resistant to galectin-1-induced death. However, the role played by aberrant cell surface glycosylation in resistance of Sezary cells to galectin-1 has not been examined. In this study, we demonstrated abundant galectin-1 in mycosis fungoides skin lesions, indicating that Sezary cells are exposed to galectin-1 in vivo. To determine specific characteristics of Sezary cells that contribute to galectin-1 resistance, we assessed CD7 expression and cell surface glycosylation of Sezary cells in mycosis fungoides lesions and of four Sezary T cell lines. Sezary cells in primary lesions and Sezary T cell lines demonstrated a characteristic "glycotype" with sialylated core 1 O-glycans that promote galectin-1 resistance. Expression of CD7 was necessary but not sufficient for galectin-1-induced death of Sezary cell lines. In addition, CD7 ؊ Sezary cell lines, and Sezary cells within mycosis fungoides lesions, expressed galectin-1, whereas CD7-positive Sezary cell lines did not express galectin-1. We propose that both loss of CD7 expression and altered cellular glycosylation contribute to apoptosis resistance of malignant T cells in mycosis fungoides.

show abstract

Clinical Characteristics and Long-term Outcome of Patients With Generalized Patch and/or Plaque (T2) Mycosis Fungoides

Cited by 148 publications

References 19 publications

Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma

Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma

Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma

Galectin-1–Mediated Apoptosis in Mycosis Fungoides: The Roles of CD7 and Cell Surface Glycosylation

Contact Info

Product

Resources

About